Impact of Portulaca oleracea L. extract in patients with irritable bowel syndrome
Intestinal Research · 31.10.2026 · 24 (4) · 799-812
DOI: 10.5217/ir.2025.00200 ↗Kurz gefasst
Fachartikel in der Zeitschrift Intestinal Research, erschienen am 31.10.2026. Verfasst von Kwangwoo Nam und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology, Dankook University Hospital, Dankook University College of Medicine, Cheonan, Korea. Die Arbeit nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Ministry of Agriculture, Food and Rural Affairs, Korea Pharmaceutical Co., Ltd..
Abstract (Originalsprache)
Background/Aims: Portulaca oleracea is known to have anti-inflammatory and immunoregulatory effects, and also showed positive effect on complete spontaneous bowel movement and bowel symptoms in patients with chronic constipation in a previous study. Thus, we aimed to investigate the impact of P. oleracea in patients with irritable bowel syndrome (IBS).
Methods
Patients with IBS defined by ROME IV criteria were enrolled between July 2022 and April 2023. Patients were randomly assigned to P. oleracea or placebo group and took drugs for 8 weeks. Clinical data including gastrointestinal and IBS symptoms, laboratory tests including inflammatory and immunologic laboratory markers, and stool tests including fecal calprotectin and stool microbial analysis were evaluated at the baseline, week 4, and week 8.
Results
A total of 108 patients were initially enrolled and 101 patients were finally included in the analysis. There was significant improvement during 8 weeks in P. oleracea group compared to placebo group in the aspect of gastrointestinal and IBS-related bowel symptoms (Gastrointestinal Symptom Rating Scale total score: from 44.1 to 31.7 vs. from 41.4 to 39.9; IBS-Symptom Severity Score total score: from 232.0 to 120.6 vs. from 202.7 to 178.2), especially in the aspect of abdominal pain. Interleukin-6 (IL-6) was significantly decreased during 8 weeks in P. oleracea group, although there was no significant difference between 2 groups. In addition, increase in IL-6 during study period was significantly associated with dysbiosis in stool microbial analysis. There was no significant adverse event.
Conclusions
P. oleracea has positive impact in patients with IBS showing improvement of immunologic cytokine and stool microbiome.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Gastroenterology, Dankook University Hospital, Dankook University College of Medicine, Cheonan, Korea.
- Research Institute R&D Center, Korea Drug Co., Ltd., Seoul, Korea.
- Wonkwang Digestive Disease Research Institute, Iksan, Korea.
- Good Breath Clinic, Gunpo, Korea.
- Research Institute of Clinical Medicine, Dankook University Hospital, Cheonan, Korea.
- Department of Gastroenterology, Dankook University Hospital, Dankook University College of Medicine, Cheonan, Korea. dreun1028@hanmail.net.
Förderung
- Ministry of Agriculture, Food and Rural Affairs
- Korea Pharmaceutical Co., Ltd.
Zitieren
APA
Nam, K., Choi, J. H., Kim, Y. S., Lee, S., Park, J. H., Kim, H., Lee, S., Lee, Y., Lee, D., Ryou, S., & Shin, J. E. (2026). Impact of Portulaca oleracea L. extract in patients with irritable bowel syndrome. Intestinal Research, 24(4), 799-812. https://doi.org/10.5217/ir.2025.00200
Vancouver
Nam K, Choi JH, Kim YS, Lee S, Park JH, Kim H, et al. Impact of Portulaca oleracea L. extract in patients with irritable bowel syndrome. Intestinal Research. 2026;24(4):799-812. doi:10.5217/ir.2025.00200
BibTeX
@article{Nam2026,
author = {Nam, Kwangwoo and Choi, Jung Ho and Kim, Yong Sung and Lee, Seong and Park, Jee Hun and Kim, Hyeongjoo and Lee, Sangyun and Lee, Yerin and Lee, Doohyuck and Ryou, Sunghyeok and Shin, Jeong Eun},
title = {Impact of Portulaca oleracea L. extract in patients with irritable bowel syndrome},
journal = {Intestinal Research},
year = {2026},
volume = {24},
number = {4},
pages = {799--812},
doi = {10.5217/ir.2025.00200}
}
EUVIMED